ALT5 Sigma (NASDAQ:ALTS) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of ALT5 Sigma (NASDAQ:ALTS) in a research note issued to investors on Thursday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded shares of ALT5 Sigma from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

ALT5 Sigma Trading Down 3.8%

NASDAQ:ALTS opened at $2.30 on Thursday. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 1.45. The stock’s 50-day simple moving average is $3.70 and its 200 day simple moving average is $6.07. ALT5 Sigma has a 52-week low of $1.80 and a 52-week high of $10.95.

Insider Activity at ALT5 Sigma

In other news, Director David C. Danziger acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, August 14th. The stock was bought at an average price of $7.30 per share, with a total value of $73,000.00. Following the transaction, the director directly owned 20,000 shares in the company, valued at approximately $146,000. The trade was a 100.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.65% of the stock is currently owned by company insiders.

Institutional Trading of ALT5 Sigma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Arkadios Wealth Advisors bought a new stake in shares of ALT5 Sigma during the 3rd quarter worth about $62,000. Bridgeway Capital Management LLC grew its position in shares of ALT5 Sigma by 9.4% in the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after purchasing an additional 1,661 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of ALT5 Sigma in the second quarter valued at approximately $380,000. Geode Capital Management LLC grew its position in shares of ALT5 Sigma by 27.6% in the second quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock valued at $1,412,000 after purchasing an additional 42,157 shares during the last quarter. Finally, Evernest Financial Advisors LLC acquired a new position in shares of ALT5 Sigma in the second quarter valued at approximately $87,000. Institutional investors own 6.27% of the company’s stock.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.